Juniper Pharmaceuticals (NASDAQ:JNP) was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating in a note issued to investors on Monday.

JNP has been the topic of a number of other research reports. ValuEngine raised Juniper Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 9th. Roth Capital raised their target price on Juniper Pharmaceuticals from $12.00 to $24.00 and gave the company a “buy” rating in a report on Friday, March 9th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $29.00.

How to Become a New Pot Stock Millionaire

Juniper Pharmaceuticals (JNP) opened at $11.00 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.68 and a current ratio of 2.00. The company has a market capitalization of $119.63, a PE ratio of -61.11 and a beta of 0.58. Juniper Pharmaceuticals has a fifty-two week low of $3.65 and a fifty-two week high of $11.15.

Juniper Pharmaceuticals (NASDAQ:JNP) last issued its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.22. The business had revenue of $11.79 million for the quarter, compared to analyst estimates of $16.00 million. Juniper Pharmaceuticals had a negative return on equity of 3.95% and a negative net margin of 4.12%. analysts expect that Juniper Pharmaceuticals will post 3.5 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JNP. Goldman Sachs Group Inc. lifted its position in shares of Juniper Pharmaceuticals by 3.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock worth $110,000 after acquiring an additional 715 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Juniper Pharmaceuticals by 1.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 72,875 shares of the specialty pharmaceutical company’s stock worth $368,000 after acquiring an additional 1,344 shares during the period. Macquarie Group Ltd. lifted its position in shares of Juniper Pharmaceuticals by 21.7% in the 4th quarter. Macquarie Group Ltd. now owns 34,585 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 6,166 shares during the period. Deutsche Bank AG lifted its position in shares of Juniper Pharmaceuticals by 112.1% in the 4th quarter. Deutsche Bank AG now owns 37,181 shares of the specialty pharmaceutical company’s stock worth $180,000 after acquiring an additional 19,653 shares during the period. Finally, Algert Global LLC lifted its position in shares of Juniper Pharmaceuticals by 20.4% in the 3rd quarter. Algert Global LLC now owns 144,565 shares of the specialty pharmaceutical company’s stock worth $658,000 after acquiring an additional 24,530 shares during the period. 39.67% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “TheStreet Upgrades Juniper Pharmaceuticals (JNP) to “B-“” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/03/14/thestreet-upgrades-juniper-pharmaceuticals-jnp-to-b.html.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.